Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
企業コードAVR
会社名Anteris Technologies Global Corp
上場日Dec 13, 2024
最高経営責任者「CEO」Paterson (Wayne G)
従業員数136
証券種類Ordinary Share
決算期末Dec 13
本社所在地860 Blue Gentian Road
都市EAGAN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号55121
電話番号16514930606
ウェブサイトhttps://anteristech.com/
企業コードAVR
上場日Dec 13, 2024
最高経営責任者「CEO」Paterson (Wayne G)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし